Ozempic’s new frontier: The war on aging
Research suggests potential health benefits beyond what popular diabetes and weight-loss drugs were first approved to treat.
US FDA to Hold off Action on Weight-Loss Drug Copies Pending Court Ruling
In its Monday update, the FDA clarified that state-licensed compounding pharmacies and outsourcing facilities — which make ...
The Pharma Letter14h
Russian generics producers start paying compensations to Novo Nordisk
Leading Russian drugmakers PSK Pharma and Promomed, which produce the analogues of Ozempic - a drug for the treatment of ...
Novo Nordisk shares fall on latest trial results for new obesity drug
Novo’s share price fell 8 per cent on Monday, having previously dived in December after a late-stage trial of CagriSema in overweight or obese people without diabetes found they lost an average of ...
Novo Nordisk shares fall on weight-loss drug trial
Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.